Normal levels and function of endothelial progenitor cells in patients with psoriatic arthritis

Ablin, Jacob N.; Goldstein, Zacharinka; Aloush, Valerie; Matz, Hagit; Elkayam, Ori; Caspi, Dan; Swartzenberg, Shmuel; George, Jacob; Wohl, Yonit

doi:10.1007/s00296-008-0676-7

Cited by 19 publications

(37 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD133+/KDR+ progenitor cells have been demonstrated to differentiate in endothelial cells both in vitro and in vivo, contribute to reendothelialization of left ventricular assist devices and promote endothelial regeneration in sites of ischemia and vascular injury in humans [17,18]. Contrary to our method, Ablin et al [15] used another combination of surface markers that likely identifies a different subpopulation of CEPCs.…”

Section: Discussionmentioning

confidence: 66%

“…To the best of our knowledge, there is only one publication regarding the evaluation of the levels of CEPCs in patients with psoriasis. Ablin et al [15] did not show a statistically significant difference in CEPCs numbers between patients with psoriasis (n = 9), psoriatic arthritis (n = 22) and controls (n = 16). In their study CEPCs were identified as CD133+/CD34+ and CD34+/KDR+ cells in peripheral blood with flow cytometry.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Reduced Number of Circulating Endothelial Progenitor Cells (CD133+/KDR+) in Patients with Plaque Psoriasis

et al. 2012

View full text Add to dashboard Cite

Background: Psoriasis is associated with an increased cardiovascular risk. Circulating endothelial progenitor cells (CEPCs) play a significant role in the maintenance of vascular homeostasis. Objective: The aim of this study was to evaluate the number of CEPCs in patients with psoriasis compared to controls and assess possible correlations between the number of these cells and the plasma levels of vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) and clinical features of psoriasis. Methods: The number of CEPCs, identified as CD133+/KDR+ cells, was determined with flow cytometry in peripheral blood of psoriatic patients (n = 63) and controls (n = 31). The plasma levels of VEGF and sVEGFR-1 were measured with enzyme-linked immunosorbent assay. Results: The number of CEPCs was significantly reduced in psoriatic patients compared with controls (p = 0.000026) and inversely correlated with disease severity (R = –0.283; p = 0.0248). Conclusion: A reduced number of CEPCs may contribute to endothelial dysfunction in patients with psoriasis.

show abstract

Section: Discussionmentioning

confidence: 66%

Section: Discussionmentioning

confidence: 99%

Reduced Number of Circulating Endothelial Progenitor Cells (CD133+/KDR+) in Patients with Plaque Psoriasis

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Circulating EPC represents a population of bone marrow‐derived cells from peripheral blood that contributes to vascular genesis and repair and has been shown to be depleted in patients with systemic inflammatory disease . A study involving 32 patients with psoriasis (with or without arthritis) showed no significant difference of CD34 + /133 + EPC and CD34 + /KDR + EPC compared with controls . Conversely, a study involving 21 patients with mild degree of psoriasis demonstrated that CD34 + /KDR + and CD34 + /CXCR4/KDR + were lower compared with controls .…”

Section: Discussionmentioning

confidence: 99%

“…Increasing evidence is emerging to emphasize the role of endothelial progenitor cells (EPC) to maintain vascular endothelial integrity and measurement of circulating EPC can be used as a biomarker to determine subclinical atherosclerosis . Studies that evaluate circulating levels of EPC in patients with psoriasis compared with controls are however conflicting . Further, the role of EPC in relation with atherosclerosis in these patients has not been evaluated.…”

Section: Introductionmentioning

confidence: 99%

Relation between endothelial progenitor cells and arterial stiffness in patients with psoriasis

Liu

Chen

Zhen

et al. 2015

The Journal of Dermatology

View full text Add to dashboard Cite

Patients with psoriasis are prone to premature atherosclerosis. We hypothesize that depletion of circulating endothelial progenitor cells (EPC) is related to patients with psoriasis and can contribute to the development of atherosclerosis. Thirty-five plaque-type psoriasis patients (41.9 ± 5.5 years, 30 men) and 20 age- and sex-matched controls were studied. Four subpopulations of EPC, namely, CD34(+) EPC, CD133(+) EPC, CD34(+) /kinase insert domain-containing receptor (KDR)(+) EPC and CD133(+) /KDR(+) EPC were measured by flow cytometry. Arterial stiffness in psoriasis patients was assessed by heart to ankle pulse wave velocity (haPWV), augmentation index (AI) and carotid intima media thickness (IMT). Patients with psoriasis had a lower level of CD34(+) EPC (7.85 ± 2.49% vs 6.26 ± 2.13%, P = 0.02) compared with healthy controls. In patients with psoriasis, level of CD34(+) EPC was negatively related with haPWV (r = -0.43 P = 0.01) and Psoriasis Area and Severity Index (r = -0.39 P = 0.02). Multivariate regression analysis further demonstrated that haPWV was independently associated with level of CD34(+) EPC. Each percentage decrease in CD34(+) EPC accounted for an increase in haPWV of +0.02 m/s. The result demonstrated that patients with psoriasis had reduced CD34(+) EPC compared with controls. Importantly, CD34(+) EPC was independently related with haPWV in these patients. This finding suggests that EPC reduction is associated with the development of arterial stiffness in patients with psoriasis.

show abstract

“…41 However, the study had limited statistical power, and mean hemangioblastic EPC levels were found to be 29% lower in PsA patients compared with healthy controls (0.025% versus 0.035% of the blood population relative to mononuclear cells) but not psoria sis patients without articular involvement (0.019%). Perhaps EPC levels are affected by the formation of psori atic lesions but not by accompanying arthritis.…”

Section: Epc Levels In Psoriatic Arthritismentioning

confidence: 97%

Endothelial progenitor cell dysfunction in rheumatic disease

Westerweel

Verhaar

2009

Nat Rev Rheumatol

View full text Add to dashboard Cite

Rheumatic disease is characterized by inflammation and endothelial dysfunction, which contribute to accelerated atherosclerosis. Circulating endothelial progenitor cells (EPCs) can restore dysfunctional endothelium and thereby protect against atherosclerotic vascular disease. The number and function of EPCs are, however, affected in rheumatic diseases such as psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and antineutrophil cytoplasmic autoantibody-associated vasculitis. rheumatic disease is often characterized by decreased numbers, and impaired function, of EPCs, although numbers of these cells might increase during the initial years of systemic sclerosis. Pioneering studies show that EPC dysfunction might be improved with pharmacological treatment. How best to restore EPC function, and whether achieving this aim can prevent long-term cardiovascular complications in rheumatic disease, remain to be established.

show abstract

Normal levels and function of endothelial progenitor cells in patients with psoriatic arthritis

Cited by 19 publications

References 23 publications

Reduced Number of Circulating Endothelial Progenitor Cells (CD133+/KDR+) in Patients with Plaque Psoriasis

Reduced Number of Circulating Endothelial Progenitor Cells (CD133+/KDR+) in Patients with Plaque Psoriasis

Relation between endothelial progenitor cells and arterial stiffness in patients with psoriasis

Endothelial progenitor cell dysfunction in rheumatic disease

Contact Info

Product

Resources

About